These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7259835)

  • 1. Drug resistance in multiple myeloma associated with high in vitro incorporation of 3H-thymidine.
    Hofmann V; Salmon SE; Durie BG
    Blood; 1981 Sep; 58(3):471-6. PubMed ID: 7259835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new basis for treatment of multiple myeloma.
    Salmon SE; Durie BG; Hamburger AW
    Schweiz Med Wochenschr; 1978 Oct; 108(41):1568-72. PubMed ID: 694483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myeloma.
    Millar BC; Bell JB; Maitland JA; Zuiable A; Gore ME; Selby PJ; McElwain TJ
    Br J Haematol; 1989 Feb; 71(2):213-22. PubMed ID: 2923807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study.
    Alberts DS; Salmon SE
    Cancer Chemother Rep; 1975; 59(2 Pt 1):345-50. PubMed ID: 1097093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VBAMDex chemotherapy in advanced multiple myeloma.
    Peest D; Schmoll HJ; Schedel I; Glück S; Schumacher K; Deicher H
    Eur J Haematol; 1988 Mar; 40(3):245-9. PubMed ID: 3356240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloma cell resistance to melphalan, BCNU and epirubicin determined in vitro with the 3H-thymidine incorporation technique prior to chemotherapy.
    Gola A; Kuliczkowski K; Sedek K
    Neoplasma; 1992; 39(1):35-8. PubMed ID: 1528303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro cloning and chemosensitivity of human myeloma stem cells.
    Salmon SE
    Clin Haematol; 1982 Feb; 11(1):47-63. PubMed ID: 6176384
    [No Abstract]   [Full Text] [Related]  

  • 8. M-2 protocol for melphalan-resistant and relapsing multiple myeloma.
    Cavo M; Galieni P; Tassi C; Gobbi M; Tura S
    Eur J Haematol; 1988 Feb; 40(2):168-73. PubMed ID: 3345830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors with high-dose melphalan for refractory multiple myeloma.
    Barlogie B; Alexanian R; Smallwood L; Cheson B; Dixon D; Dicke K; Cabanillas F
    Blood; 1988 Dec; 72(6):2015-9. PubMed ID: 3196876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy for multiple myeloma.
    Alexanian R; Salmon S; Bonnet J; Gehan E; Haut A; Weick J
    Cancer; 1977 Dec; 40(6):2765-71. PubMed ID: 589554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro determination of myeloma cell resistance to melphalan using the 3H-thymidine incorporation technique.
    Gola A; Kuliczkowski K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(1):167-72. PubMed ID: 1695172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.
    Steinke B; Busch FW; Becherer C; Ostendorf P; Waller HD
    Cancer Chemother Pharmacol; 1985; 14(3):279-81. PubMed ID: 3838922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.
    Lee BJ; Sahakian G; Clarkson BD; Krakoff IH
    Cancer; 1974 Feb; 33(2):533-8. PubMed ID: 4812771
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chemotherapy of multiple bone myeloma. Historical and present day aspects. (Second part) (author's transl)].
    Bataille R; Morlock G; Rosenberg F; Sany J; Serre H
    Sem Hop; 1979 Sep 18-25; 55(31-32):1377-82. PubMed ID: 228415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
    Buonanno G; Tortarolo M; Valente A; Castaldo C; Russolillo S; Gonnella F
    Haematologica; 1978 Feb; 63(1):45-55. PubMed ID: 417971
    [No Abstract]   [Full Text] [Related]  

  • 17. Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma.
    Presant CA; Klahr C
    Cancer; 1978 Sep; 42(3):1222-7. PubMed ID: 698913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prednisone pulse therapy for refractory myeloma.
    Alexanian R; Yap BS; Bodey GP
    Blood; 1983 Sep; 62(3):572-7. PubMed ID: 6882916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD).
    Bladé J; San Miguel J; Sanz-Sanz MA; Alcalá A; Hernández JM; Martínez M; García-Conde J; Moro J; Ortega F; Fontanillas M
    Eur J Cancer; 1992; 29A(1):57-60. PubMed ID: 1445746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
    Barlogie B; Smith L; Alexanian R
    N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.